Mebuki Financial Group Stock (OTC: MEBUF)

Latest news for Mebuki Financial Group (OTC:MEBUF) Stock

Mebuki Financial Group Inc is a Japan-based company, engages in the provision of banking and other financial services including credit card services in Japan. Its services include loans and bills discounted, deposits, other loans, and assets. It also engages in call money transactions in the short-term markets; and invests in securities primarily comprising bonds, as well as money markets. Its other services include foreign currency exchange and international remittances.

MEBUKI FINANCIAL GRP INC by Mebuki Financial Group Inc.

Mebuki Financial Group Inc

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Global Affairs President Nick Clegg flagged the company&#8217;s evolving role in content moderation amid global elections, the latest of which was the <a target="_blank" href="https://about.fb.com/news/2024/12/2024-global-elections-meta-platforms/" rel="noreferrer noopener">U.S. presidential election</a>.
Clegg acknowledged the company&#8217;s responsibility as an operator of platforms where public exchange of views occurs amid elections in the world&#8217;s biggest democracies, including India, Indonesia, Mexico, and the European Union.&nbsp;&nbsp;
Previously, social media companies drew flak globally for spreading misinformation and content that perpetrated violence during elections.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42295863/apple-might-have-to-commit-1-billion-to-indonesia-to-reverse-iphone-16-ban" rel="noreferrer noopener">Apple Might Have To Commit $1 Billion To Indonesia To Reverse iPhone 16 Ban</a>
Facebook had suspended Donald Trump&#8217;s (then U.S. President) account from January 6, 2021, to January 7, 2023, following the Capitol Hill riot <a target="_blank" href="https://www.benzinga.com/news/21/06/21433780/facebook-suspends-trumps-accounts-for-2-years-former-president-calls-it-an-insult" rel="noreferrer noopener">in January 2021</a>. X, formerly&nbsp;known as Twitter, also banned Trump&#8217;s account after Facebook.
Therefore, Clegg acknowledged that the company had evolved its approach to elections since 2016 via trial and error, including forming a team of experts from its intelligence, data science, content and public policy, and legal teams.
In 2024, Meta ran multiple election operations centers globally amid primary elections, including the U.S., Bangladesh, Indonesia, India, Pakistan, and the EU Parliament.
Meta updated and applied its content policies throughout the year to help users freely communicate and exchange views.
Meta introduced political content controls on Facebook, Instagram, and Threads in the U.S. to recommend political content based on users&#8217; choices, the blog read. It is amid efforts to roll out the feature globally.&nbsp;
Meta permitted social media users to question or flag doubts about election processes, avoiding election-related speculation or bias that could promote violence.
For paid content, Meta&nbsp;barred&nbsp;ads that questioned the legitimacy of an election, something the company had done since 2020.
Meta revised its&nbsp;penalties system&nbsp;in 2023 to enable an effective exchange of views while punishing the policy violators. The company conducted annual audits of words it considered slurs under its Hate Speech policy.
Meta also&nbsp;revised its penalty protocol for public figures suspended for violations.
Clegg also acknowledged monitoring deepfakes and AI-enabled disinformation campaigns during the elections that helped combat potential threats from the misuse of generative AI.
Meanwhile, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) chief and owner of X, Elon Musk, has actively promoted free speech and Trump during his <a target="_blank" href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther" rel="noreferrer noopener">2024 presidential campaigns</a>.
Meanwhile, Trump now expresses his views on Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) Truth Social, where he has <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/10/41333815/whats-going-on-with-trump-media-technology-group-stock-on-tuesday" rel="noreferrer noopener">a majority stake</a>.
Price Action: META stock closed higher by 3.61% at $613.65 on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42292183/citi-trends-q3-earnings-tops-estimates-margin-expansion-revises-guidance" target="_blank" rel="noreferrer noopener">Citi Trends Sales Beat Estimates With Margin Gains Despite Q3 Loss</a></li>
</ul>
Photo via Shutterstock

News

Tech

TSLA

Meta Platforms Talks Political Misinformation, Content Moderation In Latest Blog

Topline results demonstrated a statistically significant lower "Drug Liking" for the clinical doses of oral nalbuphine (81mg and 162mg) compared to 6mg IV butorphanol. The supratherapeutic dose of oral nalbuphine (486mg) was numerically lower than the 6mg IV butorphanol for "Drug Liking" but the results were not statistically significant.
Secondary endpoints included&nbsp;pharmacodynamic markers and patient reported outcomes, which were generally consistent with the primary endpoint. No serious adverse events were reported in the study.

TRVI

Trevi Therapeutics Reports Results From  Human Abuse Potential Study Of Oral Nalbuphine; Statistically Significant Lower 'Drug Liking' For 81Mg And 162Mg Doses Of Oral Nalbuphine Vs. Butorphanol Covering Clinical Dose Range

NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS&#xAE; System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.
The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS.
NeuroPace received a $9.3 million National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies&#xAE; <a href="https://www.globenewswire.com/Tracker?data=w3qN0nEC75XJaIt7q6KRHCZ4H0uag9XxaWKGEZo6HH8AOctWZP3KjH72ghrvCHhLQq6ttLKNmiA1Eqc05sriPJRCNAJr-R38uNjkfeTyNMI=">(BRAIN) Initiative</a> to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS.

Biotech

Contracts

General

NPCE

NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome;  Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its Responsive Neuromodulation Technology In Those Who Suffer From LGS

Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Torrid Holdings missed estimated earnings by -133.0%, reporting an EPS of $-0.01 versus an estimate of $0.03.
Revenue was down $11.64 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.
Here's a look at Torrid Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.07</td>
<td>-0.08</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.12</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>285.37M</td>
<td>282.40M</td>
<td>274.83M</td>
<td>245.83M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>284.64M</td>
<td>279.77M</td>
<td>293.54M</td>
<td>275.41M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Torrid Holdings <a href="https://www.benzinga.com/quote/CURV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CURV

Torrid Holdings Earnings Analysis: Q3 Recap

Guidance

Torrid Holdings Sees Q4 Revenue $255M-$270M Vs $290.63M Est.

IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (ACN 629 842 799) ("IREN") today announced its intention to offer, subject to market and other conditions, $300&nbsp;million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). IREN also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45&nbsp;million principal amount of notes.
The notes will be senior, unsecured obligations of IREN, will accrue interest payable semi-annually in arrears and will mature on June 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. IREN will settle conversions by paying or delivering, as the case may be, cash, its ordinary shares or a combination of cash and its ordinary shares, at its election.

Offerings

IREN

IREN Announces Its Intention To Offer $300M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

WIIM

BASE

Couchbase shares are trading lower after the company issued Q4 revenue guidance below estimates.

Insider Trades

Goldman Sachs CEO David Solomon Sells 6,550 Shares For ~$4M At $610.91 Each, Retains 117,883 Shares Directly And 16,171 Indirectly Through Family Trust

Salesforce shares are trading higher after the company reported Q3 earnings and raised its guidance.

<a href="https://www.globenewswire.com/Tracker?data=8Tf7Z3_YTnk-drIFCyK3YwK5fBKtJERg8a5F3K8syiG68jnjCZnBJKIYCATZd01jimcmqpP1528lJYHqXWY-ma414azilZr-CI5Zg79wOZw=">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, <a href="https://www.globenewswire.com/Tracker?data=0eWtnXxZi0DLMosegLjoiOoxfutWhH7qSlf7dqC2xfyHNQu-tfX-H-3N7YMQ4Mml7pdz18Wt2RW-5K2mAnTcbFd--zxV1VGeBPo_CnnN2LU=">click here</a>.
Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF).
The event will focus on Tectonic's lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study.
A live question and answer session will follow the formal presentations.

TECX

Tectonic Therapeutic To Host KOL Event On The Unmet Need In Group 2 PH-HFpEF And TX45 As A Potential Treatment On Thursday, December 12, 2024 From 4:00 PM To 6:00 PM ET

The partnership also includes the successful demonstration of Parsons' software-defined satellite communications solution using Globalstar's Low Earth Orbit (LEO) satellite constellation.

GSAT

Parsons, Globalstar Enter Exclusive Partnership To Support The Public, Government, And Defense Sectors

Torrid Holdings Sees FY24 Revenue $1.083B-$1.098B Vs $1.139B Est.

PSTG

Public Storage shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

Salesforce Raises Full Year FY25 GAAP Operating Margin Guidance To 19.8% And Raises non-GAAP Operating Margin Guidance to 32.9%

Salesforce Raises Low End Of Full Year FY25 Revenue Guidance to $37.8B-$38.0B, Up 8%- 9% Y/Y

&nbsp;8.4 EH/s Capacity Achieved With 68% YoY Growth, $41K Power Cost Per Bitcoin, And 7,400 S21 Pro Miners Installed

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

WULF

TeraWulf Reports November 2024 Update Of 115 Bitcoin Mined

Salesforce shares are trading higher after the company reported better-than-expected Q3 sales results.

Couchbase Tightens FY25 Total Revenue Outlook From $205.1M - $209.1M To $207.2M - $208.0M, Est $207.658M

Full-Year Fiscal 2025 Guidance: Based on the company's first quarter performance, Campbell's is re-affirming its full-year fiscal 2025 guidance provided on August 29, 2024. Guidance ranges reflect a balance between expected sequential progress and pragmatism as the company continues to navigate the dynamic consumer environment and uneven category recovery. The upper end of the range anticipates a quicker normalization of the consumer environment while the lower end of the range assumes a slower, more conservative pace of recovery.

The Campbell's Company Says Based On The Company's Q1 Performance, Campbell's Is Re-Affirming Its FY25 Guidance Provided On August 29, 2024

MRVL

Marvell Technology shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

Comments

Mebuki Financial Group

News

Latest news for Mebuki Financial Group (OTC:MEBUF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga